Intra-Cellular Therapies Earning Date (ITCI)

USA |NASDAQ |USD

ITCI Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 8, 2022 Jun 2022 - - $-0.85
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 8, 2022 Jun 2022 - - $19.01M

Intra-Cellular Therapies's next earnings date is Monday, Aug 8, 2022 for the fiscal quarter ending Jun 2022.

ITCI Earnings Date & History Chart

ITCI Earnings & Revenue Forecast

ITCI Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 9 $-3.06 $-3.68 $-2.18

ITCI Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 2 $-2.97 $-2.44 $-2.45

ITCI Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 8 $221.95M $178.10M $261.56M

ITCI Earnings Date & Revenue History

ITCI Earnings History

|
Show More
Show More

ITCI Revenue History

|
Show More
Show More

Intra-Cellular Therapies Next Earnings Date & Report

ITCI Next Earnings Date & Report Preview: Jun 2022 (FQ)

ITCI's next earnings date is Monday, Aug 8, 2022 for the fiscal quarter ending Jun 30, 2022.

Intra-Cellular Therapies Previous Earnings Dates & Reports

ITCI Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Intra-Cellular Therapies's previous earnings date was May 9, 2022 for its fiscal quarter ended Mar 31, 2022.

ITCI Previous Earnings Date & Report Recap: Dec 2021 (FY)

Intra-Cellular Therapies's previous annual earnings date was Mar 1, 2022 for its fiscal year ended Dec 31, 2021.

ITCI's earnings per share (EPS) was $-3.50, missing the consensus analysts forecast of $-3.45 by 1.45% , and lower than the previous year's EPS (Dec 2020) by 8.02%.

Revenues were $83.80M, better than the forecast of $83.34M by 0.56%, and up by 271.95% from previous year's revenue.

The company reported a net income of $-284.13M.

Intra-Cellular Therapies reported a free cash flow of $-259.87M for its fiscal year, compared to $-230.34M a year ago.